ClinicalTrials.gg
Active, not recruitingNCT07299097HYPNOSUpdated Oct 30, 2026

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

An observational study in Narcolepsy Type 1 and Narcolepsy Type 2, sponsored by Takeda. Active, not recruiting at 10 sites in Spain. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Takeda · Observational

Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
402
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.

Started
2025
with 1 other
Observational
4 of 16
1 open now
Registered
13th of 16
by date

Among the 16 studies in Narcolepsy by Takeda, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 13th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Narcolepsy by Takeda, or all of them as a file.
02

Study summary

The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year. Narcolepsy is a rare sleep disorder that causes excessive daytime sleepiness. The researchers will look at medical records from hospitals across Spain to count participants with these conditions and understand patterns in diagnosis over time.

Read the detailed description

The aim is to do epidemiology study in the core group thus the enrolment number is not applicable to this group, however approximately100 participants in the supplementary group (online survey).

03

Conditions studied

  • Narcolepsy Type 1
  • Narcolepsy Type 2

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with NT1 and NT2 from Spain.

Eligibility criteria

- Core Group:

Inclusion Criteria:

  1. Participants with NT1 or NT2 following International Classification of Sleep Disorders, 3rd Edition (ICSD-3) or ICSD-3 text revision (ICSD-3-TR) criteria who are alive at any point during 2023 or 2024.
  2. Any age, ethnicity and nationality.
  3. Treated / under follow-up in the study site and residing in the hospitals' reference areas. Consideration will be given if participants have changed their address or reached adulthood.

Exclusion Criteria

1. NT1 or NT2 participants who do not reside in the hospitals' reference areas.

- Supplementary Group:

Inclusion criteria:

  1. Confirmation to have a diagnosis of NT1 or NT2 by a specialist.
  2. Participants greater than equal to (≥) 18 years or parents of narcolepsy participants under 18 years of age.
  3. Any gender, ethnicity or nationality.
  4. Residence in Spain.

Exclusion criteria:

1. Participants without a confirmed NT1 or NT2 diagnosis by a specialist.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
402 participants (actual)
Patient registry
No

Groups and cohorts

  • Core Group

    Participants with Narcolepsy Type (NT1) and Narcolepsy Type (NT2) of any age, ethnicity and nationality, treated / under follow-up in approximately 10 Spanish public hospitals, who are alive at any point during 2023 or 2024, residing in the hospitals' reference areas will be retrospectively observed through chart reviews. The retrospective data for up to approximately 10 years would be assessed.

    Other: No intervention

  • Supplementary Group

    Participants with NT1 and NT2 from Spain will undergo an online survey conducted in collaboration with a patient advocacy group.

    Other: No intervention

Interventions

  • OtherNo intervention

    As this is an observational study, no intervention will be administered.

06

What researchers measure

Primary outcomes

  1. Core Group: Prevalence of Participants With NT1 and NT2 per 100,000 Population

    The overall study prevalence will be calculated as the number of participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of people living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.

    Time frame: Up to 1 year

  2. Core Group: Prevalence of Adult Participants With NT1 and NT2 per 100,000 Adult Population

    The overall study prevalence will be calculated as the number of adult participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of adult people living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.

    Time frame: Up to 1 year

  3. Core Group: Prevalence of Paediatric/Adolescent Participants With NT1 and NT2 per 100,000 Paediatric/Adolescent Population

    The overall study prevalence will be calculated as number of diagnosed paediatric/adolescent participants from all public hospitals divided by number of paediatric/adolescent living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.

    Time frame: Up to 1 year

  4. Core Group: Prevalence of Male Participants With NT1 and NT2 per 100,000 Male Population

    The overall study prevalence will be calculated as the number of male participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of males living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.

    Time frame: Up to 1 year

  5. Core Group: Prevalence of Female Participants With NT1 and NT2 per 100,000 Females Population

    The overall study prevalence will be calculated as the number of female participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of females living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.

    Time frame: Up to 1 year

  6. Core Group: Incidence of NT1 and NT2 per 100,000 Population

    The incidence for both the years will be calculated as (average of both years). And for each year, the number of participants diagnosed for the first time from all hospitals divided by number of people living in the areas served by the hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.

    Time frame: Up to 2 years

  7. Core Group: Incidence of NT1 and NT2 per 100,000 Adult Population

    The incidence for both the years will be calculated as (average of both years) and for each year, the number of adult participants diagnosed for the first time from all hospitals divided by number of adults living in the areas served by these hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.

    Time frame: Up to 2 years

  8. Core Group: Incidence of Paediatric/Adolescent NT1 and NT2 per 100,000 Paediatric/Adolescent Population

    The incidence for both the years will be calculated as (average of both years) and for each year, the number of paediatric/adolescent participants diagnosed for the first time from all hospitals divided by number of paediatric/adolescent living in the areas served by these hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.

    Time frame: Up to 2 years

  9. Core Group: Incidence of Male NT1 and NT2 per 100,000 Male Population

    The incidence for both the years will be calculated as (average of both years) and for each year, the number of male participants diagnosed for the first time from all hospitals divided by number of male participants living in the areas served by these hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.

    Time frame: Up to 2 years

  10. Core Group: Incidence of Female NT1 and NT2 per 100,000 Female Population

    The incidence for both the years will be calculated as (average of both years) and for each year, the number of female participants diagnosed for the first time from all hospitals divided by number of female participants living in the areas served by these hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.

    Time frame: Up to 2 years

  11. Supplementary Group: Number of Participants with NT1 and NT2 who Attend Regular Follow-ups

    Proportion of Participants with NT1 and NT2 in Spain who attended regular follow ups at only public hospitals, only private hospitals, and both private and public hospitals will be reported.

    Time frame: On a day of survey (any 1 day) during the study for each participant

Secondary outcomes

  1. Core Group: Proportion of Participants as per Gender with NT1 and NT2 at Diagnosis

    Time frame: Up to approximately 10 years

  2. Core Group: Proportion of Participants as per Age with NT1 and NT2 at Diagnosis

    Time frame: Up to approximately 10 years

  3. Core Group: Proportion of Participants as per Gender with NT1 and NT2 at Symptom Onset

    Time frame: Up to approximately 10 years

  4. Core Group: Proportion of Participants as per Age with NT1 and NT2 at Symptom Onset

    Time frame: Up to approximately 10 years

  5. Core Group: Percentage Change in NT1 and NT2 Prevalence Over Past 10 Years

    The overall prevalence will be calculated as the number of participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of people living in the areas served by these hospitals resulting in prevalence fraction. The overall percentage change of participant resulting from the above method will be reported.

    Time frame: Up to 10 years

  6. Core Group: Percentage Change in Adult With NT1 and NT2 Prevalence Over Past 10 Years

    The overall prevalence will be calculated as the number of adult participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of adult people living in the areas served by these hospitals resulting in a study prevalence fraction. The overall percentage change of participant resulting from the above method will be reported.

    Time frame: Up to 10 years

  7. Core Group: Percentage Change in Paediatric/Adolescent NT1 and NT2 Prevalence Over Past 10 Years

    The overall prevalence will be calculated as the number of paediatric/adolescent participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of paediatric/adolescent living in the areas served by these hospitals resulting in a study prevalence fraction. The overall percentage of participant resulting from the above method will be reported.

    Time frame: Up to 10 years

  8. Core Group: Percentage Change in NT1 and NT2 Incidence Over Past 10 Years

    The incidence will be calculated as number of participants diagnosed for the first time from all hospitals divided by number of people living in the areas served by these hospitals resulting in a study incidence fraction. The overall percentage change of participant resulting from the above method will be reported.

    Time frame: Up to 10 years

  9. Core Group: Percentage Change in Adult NT1 and NT2 Incidence Over Past 10 Years

    The incidence will be calculated as number of adult participants diagnosed for the first time from all hospitals divided by number of adults living in the areas served by these hospitals resulting in a study incidence fraction. The overall percentage change of participant resulting from the above method will be reported.

    Time frame: Up to 10 years

  10. Core Group: Percentage Change in Paediatric/Adolescent NT1 and NT2 Incidence Over Past 10 Years

    The incidence will be calculated as number of paediatric/adolescent participants diagnosed for the first time from all hospitals divided by number of paediatric/adolescent living in the areas served by these hospitals resulting in a study incidence fraction. The overall percentage of participant resulting from the above method will be reported.

    Time frame: Up to 10 years

  11. Core Group: Diagnostic Delay for Incident Participants with NT1 and NT2

    Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.

    Time frame: Up to approximately 10 years

  12. Core Group: Diagnostic Delay for Incident Adult Participants with NT1 and NT2

    Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.

    Time frame: Up to approximately 10 years

  13. Core Group: Diagnostic Delay for Incident Paediatric/Adolescent Participants with NT1 and NT2

    Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.

    Time frame: Up to approximately 10 years

  14. Core Group: Diagnostic Delay for Incident Male Participants with NT1 and NT2

    Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.

    Time frame: Up to approximately 10 years

  15. Core Group: Diagnostic Delay for Incident Female Participants with NT1 and NT2

    Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.

    Time frame: Up to approximately 10 years

  16. Core Group: Percentage Change in Diagnostic Delay for Participants With NT1 and NT2 Over Past 10 Years

    Time frame: Up to 10 years

  17. Core Group: Percentage Change in Diagnostic Delay for Adult Participants With NT1 and NT2 Over Past 10 Years

    Time frame: Up to 10 years

  18. Core Group: Percentage Change in Diagnostic Delay for Paediatric/Adolescent Participants With NT1 and NT2 Over Past 10 Years

    Time frame: Up to 10 years

  19. Core Group: Percentage Change in Diagnostic Delay for Male Participants With NT1 and NT2 Over Past 10 Years

    Time frame: Up to 10 years

  20. Core Group: Percentage Change in Diagnostic Delay for Female Participants With NT1 and NT2 Over Past 10 Years

    Time frame: Up to 10 years

  21. Supplementary Group: Proportion of Participants With NT1 and NT2 who Were Diagnosed at Public hospitals and Private Practices

    Time frame: On a day of survey (any 1 day) during the study for each participant

  22. Supplementary Group: Proportion of Participants who Choose to be Followed in Public, Private, or Both Types of Hospitals and Reasons

    Time frame: On a day of survey (any 1 day) during the study for each participant

  23. Supplementary Study: Age at Symptom Onset

    Time frame: On a day of survey (any 1 day) during the study for each participant

  24. Supplementary Study: Age at Diagnosis

    Time frame: On a day of survey (any 1 day) during the study for each participant

  25. Supplementary Study: Proportion of Participants as per Speciality of the Doctor Visited First for Narcolepsy Symptoms

    Time frame: On a day of survey (any 1 day) during the study for each participant

  26. Supplementary Study: Proportion of Participants as per Speciality of the Doctor who Diagnosed Narcolepsy

    Time frame: On a day of survey (any 1 day) during the study for each participant

  27. Supplementary Study: Number of Doctors Visited by Participant Prior to Receiving a Narcolepsy Diagnosis

    Time frame: On a day of survey (any 1 day) during the study for each participant

  28. Supplementary Study: Proportion of Participants With Misdiagnosis Prior to Narcolepsy Diagnosis

    Time frame: On a day of survey (any 1 day) during the study for each participant

  29. Supplementary Study: Proportion of Participants with Comorbidities

    Time frame: On a day of survey (any 1 day) during the study for each participant

  30. Supplementary Study: Proportion of Participants as per Place of Residence (Autonomous Community)

    Time frame: On a day of survey (any 1 day) during the study for each participant

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 23, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Dec 31, 2026was Sep 2026
CompletionEst.
Dec 31, 2026was Sep 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Dec 31, 2026
Oct 30, 2026
Study completion
Sep 30, 2026→Dec 31, 2026
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Sep 30, 2026→Dec 31, 2026
    Study completion Sep 30, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07299097
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Dec 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 30, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion